Abraham Ceesay - Nov 17, 2025 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol
RAPP
Transactions as of
Nov 17, 2025
Transactions value $
-$275,047
Form type
4
Date filed
11/18/2025, 04:27 PM
Previous filing
Oct 16, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ceesay Abraham Chief Executive Officer, Director RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON /s/ Troy Ignelzi, Attorney-in-Fact 2025-11-18 0001722140

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPP Common Stock Sale -$69.2K -2.78K -0.48% $24.92 577K Nov 17, 2025 Direct F1, F2
transaction RAPP Common Stock Sale -$77.7K -3.06K -0.53% $25.43 574K Nov 17, 2025 Direct F1, F3
transaction RAPP Common Stock Sale -$55.8K -2.24K -5.46% $24.91 38.8K Nov 17, 2025 By Dorothy Ceesay Irrevocable Trust F1, F4, F5
transaction RAPP Common Stock Sale -$72.3K -2.84K -7.32% $25.44 36K Nov 17, 2025 By Dorothy Ceesay Irrevocable Trust F1, F5, F6
holding RAPP Common Stock 81.7K Nov 17, 2025 By Ceesay Family Irrevocable Trust F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.22 to $25.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.22 to $25.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.21 to $25.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F5 Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.23 to $25.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F7 Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.